Oculus BioMed is developing the next-generation standard of ocular therapies, which are designed to better preserve and improve vision in patients with retinal and cornea disorders including diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD).

While many biotech companies pursue a single scientific platform, we are strategically building a deep and diverse pipeline of genetic therapies, novel small peptide drugs and advanced medical devices.

Oculus BioMed is developing the next-generation standard of ocular therapies, which are designed to better preserve and improve vision in patients with retinal and cornea disorders including diabetic macular edema (DME), neovascular age-related macular degeneration (nAMD).

We are a pre-clinical and clinical stage ocular company developing a pipeline of advanced therapeutics based on our proprietary OBM-1701 synthetic peptide for wAMD, OBM-17XX for dry eye disease (DED) and cornea replacement technology.

Moreover, OBM has partnered with world leading research institute – The Centre for Eye Research Australia (“CERA”) to develop “SwitchGene” eye gene therapies including but not limited to its potential use in treating diabetic retinopathy (DR).